Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Scorpion currently has STX-478, a once-daily oral medicine with a mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid ...

Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...

Other competitors, such as Scorpion Therapeutics with its STX-478, are also advancing similar PI3K inhibitors. However, Relay maintains a significant time advantage in clinical development ...

Meanwhile, Lilly announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor STX-478 for $2.5 billion, with its non-PI3Kα drugs spun off into a new company. STX-478 is currently in Phase I ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...